Oppenheimer & Co. Inc. Acquires 2,244 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Oppenheimer & Co. Inc. grew its holdings in 10x Genomics, Inc. (NASDAQ:TXGGet Rating) by 28.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,047 shares of the company’s stock after acquiring an additional 2,244 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in 10x Genomics were worth $455,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after acquiring an additional 1,138,358 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of 10x Genomics by 13.9% during the second quarter. Baillie Gifford & Co. now owns 8,378,971 shares of the company’s stock worth $379,148,000 after buying an additional 1,023,207 shares during the period. Vanguard Group Inc. boosted its position in shares of 10x Genomics by 2.4% during the first quarter. Vanguard Group Inc. now owns 7,732,523 shares of the company’s stock worth $588,213,000 after buying an additional 178,481 shares during the period. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 6.2% during the second quarter. ARK Investment Management LLC now owns 3,603,286 shares of the company’s stock worth $184,452,000 after buying an additional 211,948 shares during the period. Finally, Sands Capital Management LLC boosted its position in shares of 10x Genomics by 92.4% during the first quarter. Sands Capital Management LLC now owns 3,201,394 shares of the company’s stock worth $243,530,000 after buying an additional 1,537,427 shares during the period. 74.10% of the stock is currently owned by institutional investors.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 2,715 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $95,540.85. Following the transaction, the chief executive officer now owns 966,102 shares in the company, valued at $33,997,129.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Serge Saxonov sold 2,715 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $95,540.85. Following the transaction, the chief executive officer now owns 966,102 shares in the company, valued at $33,997,129.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 1,292 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total value of $45,465.48. Following the transaction, the insider now owns 186,246 shares in the company, valued at approximately $6,553,996.74. The disclosure for this sale can be found here. Insiders have sold 4,994 shares of company stock worth $175,739 over the last 90 days. Company insiders own 11.08% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $39.74 on Thursday. The stock has a 50 day moving average price of $30.36 and a 200 day moving average price of $38.62. The stock has a market capitalization of $4.55 billion, a PE ratio of -26.85 and a beta of 1.58. 10x Genomics, Inc. has a 52 week low of $23.81 and a 52 week high of $160.92.

10x Genomics (NASDAQ:TXGGet Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. The firm had revenue of $131.10 million for the quarter, compared to analyst estimates of $129.13 million. 10x Genomics had a negative return on equity of 21.01% and a negative net margin of 33.20%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.15) earnings per share. As a group, research analysts forecast that 10x Genomics, Inc. will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TXG. Cowen upped their price objective on 10x Genomics to $55.00 in a research report on Monday, August 15th. Cowen upped their price objective on 10x Genomics from $50.00 to $55.00 in a research report on Tuesday, August 9th. Morgan Stanley reduced their price objective on 10x Genomics from $70.00 to $64.00 and set an “overweight” rating for the company in a research report on Friday, November 4th. JPMorgan Chase & Co. reduced their price objective on 10x Genomics from $65.00 to $55.00 in a research report on Thursday, November 3rd. Finally, Citigroup reduced their price target on 10x Genomics from $100.00 to $65.00 in a research report on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $51.13.

About 10x Genomics

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGGet Rating).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.